Physician profile
Thomas E Ducker
NPI 1295753887
$2,276.15
in general payments reported to CMS, 2019-2025
30 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $160 · 2021: $574 · 2022: $541 · 2023: $322 · 2024: $186 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $388.33 | 2019-2023 | Skyrizi, Rinvoq, Mavyret |
| Ferring Pharmaceuticals INC. | $365.29 | 2019-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $253.03 | 2020-2022 | |
| Madrigal Pharmaceuticals | $225.26 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $160.16 | 2019-2024 | |
| Janssen Biotech, INC. | $104.37 | 2021-2023 | Stelara, Simponi, Remicade |
| Qol Medical, LLC | $103.48 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $91.27 | 2021-2024 | Linzess |
| Shionogi INC | $77.81 | 2019 | |
| Intercept Pharmaceuticals, INC. | $68.24 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.56 | 2020-2024 | Trulance |
| Heron Therapeutics, INC. | $40.25 | 2022-2024 | Zynrelef |
| Nestle Healthcare Nutrition INC. | $38.20 | 2023 | |
| Pfizer INC. | $33.51 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $27.84 | 2025 | Iqirvo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $26.60 | 2021-2022 | |
| Romark Laboratories, Lc | $22.68 | 2019 | |
| Braintree Laboratories, INC. | $22.23 | 2019 | |
| Evoke Pharma, INC. | $19.37 | 2023 | Gimoti |
| Astrazeneca Pharmaceuticals Lp | $17.71 | 2023 | |
| Olympus America INC. | $17.53 | 2022 | |
| Bard Access Systems, INC. | $15.91 | 2019 | |
| Convatec INC. | $14.94 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.93 | 2022 | |
| Sandoz INC. | $13.60 | 2024 | Hyrimoz |
| Janssen Pharmaceuticals, INC | $13.47 | 2022 | |
| Boston Scientific Corporation | $13.13 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.12 | 2024 | Voquezna |
| Allergan, INC. | $12.03 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $8.30 | 2023 | Snares |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ducker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.